Ubs Group Ag Heron Therapeutics, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 85,253 shares of HRTX stock, worth $91,220. This represents 0.0% of its overall portfolio holdings.

Number of Shares

85,253

Previous 166,793 48.89%

Holding current value

$91,220

Previous $583,000 71.01%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.73 - $3.67 $141,064 - $299,251	-81,540 Reduced 48.89%	85,253 $169,000
Q2 2024 Aug 13, 2024	BUY	$2.32 - $3.86 $128,525 - $213,840	55,399 Added 49.73%	166,793 $583,000
Q1 2024 May 13, 2024	SELL	$1.71 - $3.06 $17,240 - $30,850	-10,082 Reduced 8.3%	111,394 $308,000
Q4 2023 Feb 09, 2024	BUY	$0.54 - $1.82 $31,541 - $106,306	58,410 Added 92.62%	121,476 $206,000
Q3 2023 Nov 09, 2023	SELL	$0.97 - $1.8 $5,791 - $10,747	-5,971 Reduced 8.65%	63,066 $64,000
Q2 2023 Aug 11, 2023	BUY	$1.11 - $2.88 $14,728 - $38,214	13,269 Added 23.79%	69,037 $80,000
Q1 2023 May 12, 2023	BUY	$1.51 - $3.25 $28,501 - $61,343	18,875 Added 51.16%	55,768 $84,000
Q4 2022 Feb 08, 2023	SELL	$2.25 - $4.67 $114,736 - $238,141	-50,994 Reduced 58.02%	36,893 $92,000
Q3 2022 Nov 10, 2022	BUY	$2.66 - $5.37 $212,337 - $428,665	79,826 Added 990.27%	87,887 $372,000
Q2 2022 Aug 10, 2022	SELL	$2.3 - $6.29 $519,935 - $1.42 Million	-226,059 Reduced 96.56%	8,061 $22,000
Q1 2022 May 16, 2022	SELL	$4.63 - $9.94 $394,184 - $846,261	-85,137 Reduced 26.67%	234,120 $1.34 Million
Q4 2021 Feb 14, 2022	BUY	$8.35 - $12.6 $594,094 - $896,477	71,149 Added 28.68%	319,257 $2.92 Million
Q3 2021 Nov 15, 2021	BUY	$10.13 - $15.0 $2.43 Million - $3.6 Million	239,993 Added 2957.4%	248,108 $2.65 Million
Q2 2021 Aug 13, 2021	SELL	$13.27 - $18.48 $1.86 Million - $2.58 Million	-139,789 Reduced 94.51%	8,115 $126,000
Q1 2021 May 12, 2021	BUY	$14.49 - $20.72 $238,418 - $340,926	16,454 Added 12.52%	147,904 $2.4 Million
Q4 2020 Feb 11, 2021	BUY	$14.61 - $22.14 $582,442 - $882,633	39,866 Added 43.53%	131,450 $2.78 Million
Q3 2020 Nov 12, 2020	SELL	$13.67 - $17.77 $311,607 - $405,067	-22,795 Reduced 19.93%	91,584 $1.36 Million
Q2 2020 Jul 31, 2020	SELL	$10.89 - $21.47 $119,147 - $234,903	-10,941 Reduced 8.73%	114,379 $1.68 Million
Q1 2020 May 01, 2020	BUY	$10.23 - $24.56 $274,000 - $657,815	26,784 Added 27.18%	125,320 $1.47 Million
Q4 2019 Feb 14, 2020	SELL	$17.42 - $26.61 $2.48 Million - $3.79 Million	-142,312 Reduced 59.09%	98,536 $2.32 Million
Q3 2019 Nov 14, 2019	BUY	$16.36 - $21.39 $1 Million - $1.31 Million	61,140 Added 34.02%	240,848 $4.46 Million
Q2 2019 Aug 14, 2019	BUY	$16.93 - $26.22 $2.08 Million - $3.22 Million	122,805 Added 215.81%	179,708 $3.34 Million
Q1 2019 May 14, 2019	SELL	$23.15 - $28.34 $3.44 Million - $4.21 Million	-148,476 Reduced 72.29%	56,903 $1.39 Million
Q4 2018 Feb 14, 2019	BUY	$22.03 - $32.01 $2.61 Million - $3.8 Million	118,661 Added 136.84%	205,379 $5.33 Million
Q3 2018 Nov 14, 2018	BUY	$30.0 - $40.85 $1.05 Million - $1.43 Million	34,942 Added 67.49%	86,718 $2.75 Million
Q2 2018 Aug 14, 2018	SELL	$26.4 - $42.0 $4.41 Million - $7.02 Million	-167,024 Reduced 76.34%	51,776 $2.01 Million
Q1 2018 May 15, 2018	BUY	$18.43 - $28.8 $3.31 Million - $5.17 Million	179,364 Added 454.82%	218,800 $6.04 Million
Q4 2017 Feb 14, 2018	SELL	$14.8 - $18.85 $89,495 - $113,985	-6,047 Reduced 13.3%	39,436 $714,000
Q3 2017 Nov 14, 2017	BUY	$14.65 - $16.85 $219,207 - $252,126	14,963 Added 49.03%	45,483 $734,000
Q2 2017 Aug 14, 2017	BUY	N/A	18,966 Added 164.15%	30,520 $423,000
Q1 2017 Nov 14, 2017	BUY	N/A	11,554	11,554 $173,000

Others Institutions Holding HRTX

# of Institutions

180

Shares Held

121M

Call Options Held

80.4K

Put Options Held

94.9K

View Full List

About HERON THERAPEUTICS, INC.

Ticker HRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,774,000
Market Cap $127M
Description
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...

More about HRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account